Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols

Figure 3

Generation of nitric oxide (NO) by NCX-4040 in A2780 WT and A2780 cDDP cells. (A) Representative EPR spectra obtained from control (NCX-4040, A2780 cDDP cells) and NCX-4040 treatment (100 μM for both A2780 WT and A2780 cDDP) groups. The cells were incubated with NCX-4040 in the presence of spin trap (MGD)2Fe. Also shown is an EPR spectrum of an authentic complex of NO with Fe(MGD)2 obtained by adding SNAP (an NO donor) to spin trap. (B) Time-course of nitric oxide release by NCX-4040 in A2780 WT, A2780 cDDP, and A2780 cDDP cells treated with 1 mM buthionine sulfoximine (BSO) for 24 h. (C) Representative DAF-FM DA fluorescence images of untreated (control) and treated (1, 2 or 4 hours) with NCX-4040 (100 μM). (D) Quantitative results on the DAF-FM DA fluorescence data. *p < 0.01 versus Control group.

Back to article page